Abstract
People with schizophrenia often experience considerable difficulties in daily life because of a wide constellation of symptoms associated with the condition. This article examines the pharmaceutical targets that are being investigated to provide greater efficacy and tolerability than the current dopamine‐focussed drugs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
